Imlunestrant

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Vepdegestrant (Veppanu) for advanced breast cancer.

Vepdegestrant (Veppanu) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics

Published: July 14, 2026

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.

Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title.

Journal: Expert opinion on pharmacotherapy

Published: May 22, 2026

Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.

Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.

Journal: Advances in cancer research

Published: May 21, 2026

Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.

Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.

Journal: Frontiers in oncology

Published: April 14, 2026

Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer.

Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer.

Journal: Drug design, development and therapy

Published: March 23, 2026

Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.

Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.

Journal: Oncology and therapy

Published: March 19, 2026

Novel Endocrine Therapies: Current Status and Future Directions.

Novel Endocrine Therapies: Current Status and Future Directions.

Journal: Clinical breast cancer

Published: February 24, 2026

Imlunestrant - ER+/HER2-, locally advanced or metastatic breast cancer with an activating ESR1 mutation

Imlunestrant - ER+/HER2-, locally advanced or metastatic breast cancer with an activating ESR1 mutation

Journal: Bulletin du cancer

Published: February 18, 2026

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

Journal: International journal of molecular sciences

Published: January 25, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Journal: International journal of clinical oncology

Published: January 08, 2026

Imlunestrant (Inluriyo) for advanced breast cancer.

Imlunestrant (Inluriyo) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Journal: ESMO open

Published: January 05, 2026

Showing 1-12 of 36

Last Updated: 09/26/2026